Yousif Capital Management LLC Purchases 21,969 Shares of The Cooper Companies, Inc. $COO

Key Points

• Yousif Capital Management increased its Cooper Companies stake by 118.8%, acquiring 21,969 additional shares for a total position of 40,461 shares valued at approximately $2.29 million.
• CooperCompanies reaffirmed its fiscal 2026 guidance while beginning a leadership transition: CEO Al White stepped down, Walt Rosebrough became executive chair, and the company plans to refresh its board. The transition follows performance that management acknowledged had not met expectations.
• Analysts maintain a consensus “Hold” rating with a $68.60 target price, compared with COO’s reported $59.41 share price. The company also authorized a $3 billion repurchase program covering up to 22.7% of outstanding shares.

Yousif Capital Management LLC lifted its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 118.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,461 shares of the medical device company's stock after acquiring an additional 21,969 shares during the quarter. Yousif Capital Management LLC's holdings in Cooper Companies were worth $2,287,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in COO. BlackRock Inc. purchased a new stake in Cooper Companies in the 2nd quarter valued at approximately $1,077,762,000. Generation Investment Management LLP purchased a new position in shares of Cooper Companies during the 2nd quarter worth approximately $356,304,000. Jupiter Topco LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $305,074,000. JANA Partners Management LP lifted its holdings in shares of Cooper Companies by 0.5% in the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company's stock valued at $256,900,000 after buying an additional 17,322 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Cooper Companies by 3.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company's stock valued at $248,758,000 after buying an additional 103,044 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reaffirmed its previously issued fiscal 2026 financial guidance, signaling that management does not currently expect the leadership transition to alter its near-term outlook. The company also appointed veteran medical-device executive Walt Rosebrough as executive chair and plans to add former Johnson & Johnson medical-device leader Shlomi Nachman to the board. CooperCompanies Announces Leadership Transition and Board Refreshment
• Neutral Sentiment: Rosebrough will oversee day-to-day operations while the company searches for a permanent CEO. Three directors plan to leave after the 2027 annual meeting, creating a smaller, refreshed seven-member board intended to improve accountability and execution. The changes could support a turnaround, but the search introduces additional uncertainty.
• Negative Sentiment: President and CEO Al White stepped down immediately, while the company acknowledged that recent performance had not met expectations. The abrupt transition may reinforce concerns about operational execution and growth, particularly as COO’s recent revenue growth has been modest.
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims alleging that CooperCompanies may have issued materially misleading business information. The announcement does not establish wrongdoing, but it adds litigation and reputational risk and could weigh on investor sentiment. Rosen securities class action investigation

Analysts Set New Price Targets

COO has been the topic of a number of recent analyst reports. Barclays raised Cooper Companies to a "hold" rating in a report on Wednesday, October 7th. Stifel Nicolaus set a $70.00 target price on Cooper Companies and gave the company a "buy" rating in a report on Thursday, September 10th. Weiss Ratings upgraded shares of Cooper Companies from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, September 18th. William Blair cut shares of Cooper Companies from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 10th. Finally, Needham & Company LLC cut their price target on shares of Cooper Companies from $86.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Cooper Companies has an average rating of "Hold" and a consensus target price of $68.60.

Insider Transactions at Cooper Companies

In other Cooper Companies news, Director Lawrence Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average cost of $53.91 per share, with a total value of $539,100.00. Following the purchase, the director owned 21,099 shares in the company, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Walter M. Rosebrough, Jr. bought 7,000 shares of the company's stock in a transaction on Friday, September 11th. The shares were acquired at an average price of $54.11 per share, with a total value of $378,770.00. Following the completion of the acquisition, the director directly owned 17,000 shares in the company, valued at $919,870. This represents a 70.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 34,701 shares of company stock valued at $1,880,039 in the last 90 days. 2.08% of the stock is currently owned by insiders.

Cooper Companies Stock Performance

COO opened at $59.41 on Thursday. The stock has a market cap of $11.30 billion, a P/E ratio of 20.28, a P/E/G ratio of 2.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The stock's 50 day simple moving average is $60.99 and its 200 day simple moving average is $69.33. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. Cooper Companies's revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies announced that its board has approved a stock repurchase plan on Wednesday, September 9th that allows the company to buy back $3 billion in shares. This repurchase authorization allows the medical device company to purchase up to 22.7% of its shares through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its shares are undervalued.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women's health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.